STOCK TITAN

Schedule 13G/A: Nantahala Holds 1.404M GRCE Shares Including Warrants

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13G/A

Rhea-AI Filing Summary

Grace Therapeutics, Inc. Schedule 13G/A reports that Nantahala Capital Management, LLC and its principals Wilmot B. Harkey and Daniel Mack together may be deemed beneficial owners of 1,404,032 shares of Grace Therapeutics common stock, representing 9.99% of the class as of June 30, 2025. The reported position is held by funds and separately managed accounts under Nantahala's control and includes 225,831 shares that may be acquired within sixty days through the exercise of warrants. The filing shows no sole voting or dispositive power; all voting and dispositive authority is reported as shared among the reporting persons.

Positive

  • Transparent disclosure of beneficial ownership at 9.99% for Nantahala and the named individuals
  • Includes exercisable warrants in the beneficial ownership total (225,831 shares), clarifying near-term potential interest

Negative

  • No sole voting or dispositive power reported; all authority is listed as shared rather than sole
  • Position is just below 10%, which may limit certain disclosure classifications (reported as Schedule 13G/A rather than a 13D)

Insights

TL;DR: Nantahala reports a just-under-10% stake (including exercisable warrants) with shared voting and dispositive power, disclosed under Schedule 13G/A.

The filing indicates passive ownership held in the ordinary course by an investment adviser and its principals. The 9.99% figure is material for disclosure thresholds and includes 225,831 shares exercisable within sixty days, which is relevant to calculating potential voting dilution. Absence of sole voting or dispositive power suggests control is not asserted by the reporting persons; the filing is consistent with a passive investor disclosure rather than an active control filing.

TL;DR: Reporting structure shows shared authority and classification as an investment adviser filing, implying compliance with passive investor rules.

The statement classifies Nantahala as an investment adviser and Messrs. Harkey and Mack as control persons only to the extent of their roles with Nantahala. The explicit inclusion of warrants exercisable within sixty days is appropriate for beneficial ownership calculation. The filing does not indicate group formation or any intention to influence issuer control, and it provides clear allocation of voting and dispositive powers as shared rather than sole.






Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)






SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G



Nantahala Capital Management, LLC
Signature:/s/ Taki Vasilakis
Name/Title:Taki Vasilakis / Chief Compliance Officer
Date:08/14/2025
Wilmot B. Harkey
Signature:/s/ Wilmot B. Harkey
Name/Title:Wilmot B. Harkey
Date:08/14/2025
Daniel Mack
Signature:/s/ Daniel Mack
Name/Title:Daniel Mack
Date:08/14/2025

FAQ

How many shares of GRCE does Nantahala Capital Management report owning?

The filing reports 1,404,032 shares beneficially owned by Nantahala and the named reporting persons.

What percentage of GRCE does the 13G/A filing represent?

The reported position represents 9.99% of the outstanding class as stated in the filing.

Does the filing include options or warrants in the ownership total for GRCE?

Yes. The total includes 225,831 shares that may be acquired within sixty days through the exercise of warrants.

Do the reporting persons claim sole voting or dispositive power over GRCE shares?

No. The filing reports 0 sole voting power and 0 sole dispositive power; all voting and dispositive power is reported as shared (1,404,032 shares).

Under what classification is Nantahala filing this statement?

Nantahala is identified as an investment adviser and the filing is submitted on Schedule 13G/A consistent with passive ownership disclosure.
Grace Therapeutics, Inc

NASDAQ:GRCE

GRCE Rankings

GRCE Latest News

GRCE Latest SEC Filings

GRCE Stock Data

56.33M
10.62M
30.28%
27.64%
0.95%
Biotechnology
Pharmaceutical Preparations
Link
United States
PRINCETON